Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of GSK Pneumococcal Vaccines in Infants
NCT01616459Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of GSK2830929A, GSK2830930A in pneumococcal infection, sponsored by GSK. Started Jul 2012; status: completed.
02
Drugs
GSK2830929AGSK2830930A
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01616459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616459.